Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 in combination with rituximab. [electronic resource]
Producer: 20180112Description: 699-707 p. digitalISSN:- 1029-2403
- Agammaglobulinaemia Tyrosine Kinase
- Animals
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Cell Line, Tumor
- Cytotoxicity, Immunologic -- drug effects
- Disease Models, Animal
- Drug Therapy, Combination
- Female
- Humans
- Imidazoles -- administration & dosage
- Killer Cells, Natural -- drug effects
- Lymphoma, Large B-Cell, Diffuse -- drug therapy
- Mice
- Neoplasm Staging
- Protein Kinase Inhibitors -- pharmacology
- Protein-Tyrosine Kinases -- antagonists & inhibitors
- Pyrimidines -- administration & dosage
- Rituximab -- administration & dosage
- Treatment Outcome
- Tumor Burden -- drug effects
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.